Wells Susan, Broad Joanna, Jackson Rod
Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland.
N Z Med J. 2006 Apr 21;119(1232):U1935.
New Zealand cardiovascular risk management guidelines advocate targeted risk assessment based primarily on age, gender, and ethnicity--and recommend drug management for people with a 5-year absolute cardiovascular disease (CVD) risk greater than 15%. To inform service planning and healthcare delivery for district health boards and primary healthcare organisations in New Zealand, we have produced population estimates of CVD prevalence and 5-year absolute CVD risk.
The 1993 Auckland Heart and Health Study provided the data for estimating CVD prevalence and absolute CVD risk distributions using the Framingham CVD risk prediction equation. These estimates were applied to population projections for 2005 based on 2001 New Zealand Census data.
Of the projected 2.09 million people aged over 35 years in New Zealand in 2005, approximately 1.5 million (72%) meet national criteria for formal CVD risk assessment. About 151,000 (7%) are estimated to have suffered a non-fatal heart attack or stroke or have angina. A further 262,000 (13%) are estimated to have a 5-year CVD risk greater than 15% based on New Zealand CVD risk charts. This represents around 1 in 5 adults over the age of 35 years in New Zealand for whom pharmacological interventions are recommended according to the New Zealand CVD risk guidelines for the prevention of new or further CVD events.
The latest published data available on the burden of CVD risk in New Zealand is now over 10 years old and does not include Maori, Pacific, and other non-European ethnic groups. Current data on the risk profile of adult New Zealanders is required for more accurate service planning. However the information reported here provides a reasonable estimate of the magnitude of the task. Although systematic identification and management of CVD risk in New Zealanders with raised CVD risk will be a major undertaking for healthcare services, it has the potential to produce significant health-gains while reducing health disparities.
新西兰心血管风险管理指南提倡主要基于年龄、性别和种族进行有针对性的风险评估,并建议对5年心血管疾病(CVD)绝对风险大于15%的人群进行药物治疗。为了给新西兰的地区卫生委员会和初级卫生保健组织的服务规划和医疗服务提供提供信息,我们得出了CVD患病率和5年CVD绝对风险的人群估计数。
1993年奥克兰心脏与健康研究提供了数据,用于使用弗明汉姆CVD风险预测方程估计CVD患病率和绝对CVD风险分布。这些估计数应用于基于2001年新西兰人口普查数据的2005年人口预测。
预计2005年新西兰35岁以上的209万人中,约150万人(72%)符合正式CVD风险评估的国家标准。估计约15.1万人(7%)曾发生过非致命性心脏病发作或中风或患有心绞痛。根据新西兰CVD风险图表,估计另有26.2万人(13%)的5年CVD风险大于15%。这相当于新西兰35岁以上成年人中约五分之一的人,根据新西兰CVD风险指南,建议对他们进行药物干预以预防新的或进一步的CVD事件。
新西兰关于CVD风险负担的最新公布数据已有10多年历史,且未包括毛利人、太平洋岛民和其他非欧洲族裔群体。需要当前关于新西兰成年人风险状况的数据来进行更准确的服务规划。然而,此处报告的信息提供了对任务规模的合理估计。尽管对CVD风险升高的新西兰人进行系统的识别和管理对医疗服务来说将是一项重大任务,但它有可能在减少健康差距的同时带来显著的健康收益。